Dr Ali Faham Alsulami

Computational & Experimental Drug Discovery for Cancer and Infectious Disease

Bioinformatics Structural Biology Medicinal Chemistry
Faculty Photo
Assistant Professor
King Abdulaziz University (KAU)
afmalsulami1@kau.edu.sa

Focus

Mechanism-first insights

From molecular structures to actionable hypotheses and experimental priorities.

Tools

Reproducible pipelines

Standardized computational workflows paired with wet-lab validation where feasible.

Collaboration

Student supervision

Self-funded and/or government-funded students are welcome for aligned projects.

Education Profile

  • King Abdulaziz University (KAU) — Assistant Professor (Current)
  • University of Cambridge — Postdoc (2022–2024)
  • University of Cambridge — Ph.D (2022)
  • University of Nottingham — MSc (2015)
  • Queen Mary University of London — BSc (2014)

Profile

Ali is an assistant professor at King Abdulaziz University. He completed his undergraduate studies in Pharmaceutical Chemistry at Queen Mary University of London in 2014. Subsequently, he pursued a master's degree in Drug Discovery Pharmaceutical Science at the University of Nottingham in 2015. In 2018, he returned to the United Kingdom to commence his doctoral studies under the guidance of Prof. Sir Tom Blundell at the University of Cambridge, based in the Department of Biochemistry at the Sanger Institute. During his doctoral tenure, his research primarily centered on Computational and Experimental Drug Discovery in Cancer and SARS-CoV-2. Following the completion of his PhD in 2022, he continued his academic journey as a Postdoctoral Researcher under Prof. Blundell's mentorship, specializing in Drug Discovery for infectious diseases, particularly Mycobacterium abscessus.

Research

Research interests

  • Structural Biology: drug targets and protein 3D structures using Cryo-EM and X-ray crystallography
  • Medicinal Chemistry: synthesis of small molecules to improve ligand–target potency
  • Bioinformatics: tools, databases, and pipelines for aging, cancer, and infectious disease

Research summary

Structure-based drug discovery is a multidisciplinary approach that merges structural biology, medicinal chemistry, and bioinformatics to design therapeutics. By decoding biomolecular 3D structures, identifying candidate targets, and designing compounds with improved efficacy and specificity, the work iterates between computational forecasts and experimental validation.

Publications

For the latest list, please see: Google Scholar

Supervision

Current PhD opportunities

Please send your CV to: afmalsulami1@kau.edu.sa

Current Student

  • Abdulelah Abdullah Alanazi (master student)
  • Nawaf Faris AlJuhani (master student)